Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 245
- Registration Number
- NCT05486065
- Locations
- 🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Velocity Clin Res Gardena, Gardena, California, United States
🇺🇸First Valley Med Grp Lancaster, Lancaster, California, United States
A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 314
- Registration Number
- NCT05468632
- Locations
- 🇲🇰
Novo Nordisk Investigational Site, Veles, North Macedonia
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 465
- Registration Number
- NCT05443334
- Locations
- 🇪🇸
Master Centre for Spain, Madrid, Spain
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
- Conditions
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT05444153
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT05443191
- Locations
- 🇫🇮
Aava Lääkärikeskus - Aava Kamppi, Annankatu 32, 00100 Helsinki, Finland, Helsinki,, Finland
🇫🇮Master Centre for Finland, Helsinki, Finland, Finland
🇫🇷Master centre for France_Paris La défense cedex, Paris, La Défense, France
A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT05435677
- Locations
- 🇨🇳
Peking University Third Hospital, Northern branch, Beijing, Beijing, China
A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 152
- Registration Number
- NCT05429593
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Brandenburg, Germany
🇩🇪Parexel International GmbH, Berlin, Germany
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1200
- Registration Number
- NCT05394519
- Locations
- 🇺🇸
John Muir Physicians Network, Concord, California, United States
🇺🇸Headlands Research California, LLC, Escondido, California, United States
🇺🇸St. Jos Heritage Hlthcr_Fllrtn, Fullerton, California, United States
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 81
- Registration Number
- NCT05371496
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
- Conditions
- Interventions
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 92
- Registration Number
- NCT05333003
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.